Precision Medicine in Oncology-Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations

Timothy A Yap^{1

2}, Amber Johnson², Funda Meric-Bernstam^{1

2}

Affiliations

¹ Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston.
² Khalifa Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston.

Editorial

Timothy A Yap et al. JAMA Oncol. 2021.

. 2021 Apr 1;7(4):507-509.

doi: 10.1001/jamaoncol.2020.7988.

Timothy A Yap^{1

2}, Amber Johnson², Funda Meric-Bernstam^{1

2}

¹ Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston.
² Khalifa Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston.

No abstract available

Comment on

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
Cobain EF, Wu YM, Vats P, Chugh R, Worden F, Smith DC, Schuetze SM, Zalupski MM, Sahai V, Alva A, Schott AF, Caram MEV, Hayes DF, Stoffel EM, Jacobs MF, Kumar-Sinha C, Cao X, Wang R, Lucas D, Ning Y, Rabban E, Bell J, Camelo-Piragua S, Udager AM, Cieslik M, Lonigro RJ, Kunju LP, Robinson DR, Talpaz M, Chinnaiyan AM. Cobain EF, et al. JAMA Oncol. 2021 Apr 1;7(4):525-533. doi: 10.1001/jamaoncol.2020.7987. JAMA Oncol. 2021. PMID: 33630025 Free PMC article.